{"id":8448,"date":"2018-06-11T01:00:00","date_gmt":"2018-07-27T09:32:25","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/07\/27\/%e6%af%8f%e5%91%a8%e6%8a%97%e4%bd%93%e8%8d%af%e8%ae%af20180604-20180610\/"},"modified":"2018-07-27T17:32:27","modified_gmt":"2018-07-27T09:32:27","slug":"%e6%af%8f%e5%91%a8%e6%8a%97%e4%bd%93%e8%8d%af%e8%ae%af20180604-20180610","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/8448\/","title":{"rendered":"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610"},"content":{"rendered":"
\n

<\/span><\/p>\n

\u4f5c\u8005 l \u653e\u7fc1\u662f\u6c34\u8d27<\/span><\/strong><\/span><\/span><\/strong><\/p>\n

\u7f16\u8f91 l<\/span><\/strong> \u7ec6\u80de\u623f\u95f4<\/span><\/strong><\/span><\/strong><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

1<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Clovis Oncology\u548cImmunomedics\u8fbe\u6210\u4e34\u5e8a\u5408\u4f5c\u7814\u7a76\u4e09\u9634\u6027\u4e73\u817a\u764c\u548c\u5c3f\u8def\u4e0a\u76ae\u764c\u65b0\u7597\u6cd5<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0cClovis Oncology\u548cImmunomedics\u516c\u53f8\u4eca\u65e5\u8fbe\u6210\u4e34\u5e8a\u5408\u4f5c\uff0c\u4ee5\u63a2\u7a76Rucaparib\u8054\u5408ADC\u836f\u7269Sacituzumab govitecan\u6cbb\u7597\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\u548c\u8f6c\u79fb\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\u7684\u53ef\u884c\u6027\u3002\u8be5\u9879\u8ba1\u5212\u5f00\u5c55\u7684I\/II\u671f\u4e34\u5e8a\u5408\u4f5c\u7814\u7a76\u7684\u521d\u671f\u5c06\u5728\u6bcf\u4e00\u4e2a\u60a3\u8005\u8eab\u4e0a\u8bc4\u4f30\u8054\u5408\u7597\u6cd5\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002<\/span><\/p>\n

 <\/span><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

2<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Celltrion<\/span>\u516c\u5e03\u4e86\u82f1\u592b\u5229\u6614\u5355\u6297\u7c7b\u4f3c\u836fCT-P13\u6700\u65b0\u7814\u7a76\u7ed3\u679c<\/span><\/strong><\/p>\n

6\u67085\u65e5\uff0c\u7f8e\u56fd\uff0cCelltrion\u516c\u53f8\u5728\u8fd1\u65e5\u7684\u6d88\u5316\u75be\u75c5\u5468\uff08DDW\uff09\u4f1a\u8bae\u4e0a\u516c\u5e03\u4e86\u5176\u751f\u7269\u7c7b\u4f3c\u836fCT-P13\u76ae\u4e0b\u5236\u5242\u548c\u9759\u8109\u5236\u5242\u6cbb\u7597\u6d3b\u52a8\u6027\u514b\u7f57\u6069\u75c5\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u6570\u636e\u3002\u8fd9\u9879\u5f00\u653e\u6807\u7b7e\u3001\u968f\u673a\u3001\u5bf9\u7167I\u671f\u4e34\u5e8a\u7814\u7a76\u65e8\u5728\u901a\u8fc7\u5efa\u7acb\u4e0eCT-P13 IV\u7ed9\u836f\u7684\u836f\u52a8\u5b66\u53ef\u6bd4\u6027\u6765\u5bfb\u627eCT-P13 SC\u7684\u6700\u4f73\u5242\u91cf\u3002\u8be5\u7814\u7a76\u540c\u65f6\u8fd8\u8bc4\u4f30\u4e86\u4e24\u79cd\u7ed9\u836f\u65b9\u5f0f\u6cbb\u7597\u6d3b\u52a8\u6027CD\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u300230\u5468\u7684\u6cbb\u7597\u7ed3\u679c\u663e\u793a\uff0c\u4e24\u79cd\u7ed9\u836f\u65b9\u5f0f\u7684\u7597\u6548\u76f8\u5f53\uff0c\u4e34\u5e8a\u7f13\u89e3\u7387\u76f8\u4f3c\uff0c\u5b89\u5168\u6027\u5206\u5e03\u4e5f\u76f8\u5f53\u3002<\/span><\/p>\n

 <\/span><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

3<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

HEMLIBRA<\/span>\u7684\u8865\u5145\u7533\u8bf7\u83b7\u5f97FDA\u6709\u9650\u5ba1\u67e5<\/span><\/strong><\/p>\n

6\u67085\u65e5\uff0c\u7f8e\u56fd\uff0c<\/span>Genentech<\/span>\u516c\u53f8\u4eca\u65e5\u5ba3\u5e03FDA\u5df2\u53d7\u7406\u8be5\u516c\u53f8<\/span>HEMLIBRA\uff08E<\/span>micizumab-kxwh<\/span>\uff09<\/span>\u7684\u8865\u5145\u751f\u7269\u5236\u5242\u8bb8\u53ef\u8bc1\u7533\uff0c\u5e76\u4e88\u4ee5\u4f18\u5148\u5ba1\u67e5\u3002\u6b64\u6b21\u7684\u8865\u5145\u7533\u8bf7\u8ba1\u5212\u5c06\u8be5\u836f\u7528\u4e8e\u65e0\u56e0\u5b50VIII\u6291\u5236\u5242\u7684\u8840\u53cb\u75c5A\u6210\u4eba\u548c\u513f\u7ae5\u7684\u6cbb\u7597\uff0cFDA\u9884\u8ba1\u5c06\u57282018\u5e7410\u67084\u65e5\u524d\u4f5c\u51fa\u6279\u51c6\u51b3\u5b9a\u3002<\/span><\/p>\n

 <\/span><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

4<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Rituxan\uff08<\/span><\/strong>Rituximab<\/span><\/strong>\uff09<\/span>\u83b7\u5f97FDA\u6279\u51c6\u7528\u4e8e\u5bfb\u5e38\u578b\u5929\u75b1\u75ae\u7684\u6cbb\u7597<\/span><\/strong><\/p>\n

6\u67088\u65e5\uff0c\u7f8e\u56fd\uff0cGenentech\u516c\u53f8\u4eca\u65e5\u5ba3\u5e03FDA\u5df2\u6279\u51c6\u5229\u59a5\u6614\u5355\u6297\uff08R<\/span>ituximab<\/span>\uff09\u7528\u4e8e\u6cbb\u7597\u6210\u4eba\u4e2d\u91cd\u5ea6\u5bfb\u5e38\u578b\u5929\u75b1\u75ae\uff08PV\uff09\uff0c\u8fd9\u662f\u4e00\u79cd\u7f55\u89c1\u7684\u3001\u4e25\u91cd\u7684\u3001\u5177\u6709\u6f5c\u5728\u751f\u547d\u5a01\u80c1\u7684\u75be\u75c5\uff0c\u5176\u7279\u5f81\u662f\u76ae\u80a4\u548c\u7c98\u819c\u8fdb\u884c\u6027\u75bc\u75db\u6027\u8d77\u6ce1\uff0c\u5229\u59a5\u6614\u5355\u6297\u662fFDA\u6279\u51c6\u7684\u9996\u4f8bPV\u751f\u7269\u7597\u6cd5\uff0c\u4e5f\u662f60\u591a\u5e74\u6765\u8be5\u75be\u75c5\u6cbb\u7597\u7684\u7b2c\u4e00\u5927\u8fdb\u5c55\u3002<\/span><\/p>\n

 <\/span><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

5<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Prolia\u00ae\uff08Denosumab\uff09<\/span>\u83b7\u5f97\u6b27\u76df\u6279\u51c6\u7528\u4e8e\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6027\u9aa8\u8d28\u758f\u677e\u75c7\u7684\u6cbb\u7597<\/span><\/strong><\/p>\n

6\u67088\u6708\uff0c\u7f8e\u56fd\uff0cAmgen\u516c\u53f8\u4eca\u65e5\u5ba3\u5e03\u6b27\u76df\u59d4\u5458\u4f1a\uff08EC\uff09\u6279\u51c6\u4e86\u4e00\u9879\u65b0\u7684Prolia \uff08Denosumab\uff09\u9002\u5e94\u75c7\uff0c\u7528\u4e8e\u6cbb\u7597\u9aa8\u6298\u98ce\u9669\u589e\u52a0\u7684\u6210\u5e74\u60a3\u8005\u957f\u671f\u5168\u8eab\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6cbb\u7597\u76f8\u5173\u7684\u9aa8\u4e22\u5931\u3002EC\u7684\u6279\u51c6\u662f\u57fa\u4e8e\u4e00\u9879\u4e09\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u9633\u6027\u7ed3\u679c\uff0c\u8be5\u7814\u7a76\u8bc4\u4f30\u4e86\u5728\u63a5\u53d7\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6cbb\u7597\u7684\u60a3\u8005\u4e2dProlia\u4e0e\u5229\u585e\u81a6\u9178\u76f8\u6bd4\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002\u957f\u671f\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6cbb\u7597\u662f\u5f15\u8d77\u9aa8\u5bc6\u5ea6\u4e0b\u964d\u548c\u9aa8\u6298\u98ce\u9669\u589e\u52a0\u7684\u72ec\u7acb\u5371\u9669\u56e0\u7d20\uff0c\u8fd9\u9879\u6279\u51c6\u4e3a\u6709\u6548\u5bf9\u6297\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6cbb\u7597\u5bf9\u9aa8\u6298\u98ce\u9669\u589e\u52a0\u60a3\u8005\u7684\u9aa8\u9abc\u635f\u5bb3\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7597\u9009\u62e9\u3002<\/span><\/p>\n

 <\/span><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

6<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u57fa\u77f3\u836f\u4e1a<\/span>\u8054\u5408<\/span>Blueprint Medicines<\/span>\u63a2\u7d22\u809d\u7ec6\u80de\u764c\u6cbb\u7597\u65b0\u7b56\u7565<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u4e2d\u56fd\uff0c\u57fa\u77f3\u836f\u4e1a\u8fd1\u65e5\u5ba3\u5e03\u4e0eBlueprint Medicines\u516c\u53f8\u8fbe\u6210\u5408\u4f5c\u610f\u5411\uff0c\u5171\u540c\u63a8\u8fdb\u5176\u65b0\u7684\u6297\u80bf\u7624\u5c0f\u5206\u5b50\u5316\u5408\u7269\uff08A<\/span>vapritinib\u3001BLU-554\u3001BLU-667<\/span>\uff09\u5728\u4e2d\u56fd\u7684\u4e34\u5e8a\u5f00\u53d1\u4e0e\u5546\u4e1a\u5316\u3002\u4e24\u5bb6\u516c\u53f8\u8ba1\u5212\u5728\u4e2d\u56fd\u542f\u52a8\u4e00\u9879\u6982\u5ff5\u9a8c\u8bc1\u6027\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u4ee5\u8bc4\u4f30BLU-554\u8054\u5408CS1001\u4e00\u7ebf\u6cbb\u7597\u809d\u7ec6\u80de\u764c\u7684\u7597\u6548\u3002CS1001\u662f\u4e00\u79cd\u6700\u63a5\u8fd1\u4eba\u4f53\u81ea\u8eab\u5929\u7136G\u578bIgG4\u7684\u5355\u6297\u836f\u7269\uff0c\u76ee\u524d\u6b63\u5904\u4e8e\u6cbb\u7597\u665a\u671f\u80bf\u7624\u7684\u4e34\u5e8a\u7814\u7a76\u4e2d\u3002<\/span><\/p>\n

 <\/span><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

7<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u6dcb\u5df4\u7624\u975e\u5316\u7597\u65b9\u6848\u4eca\u65e5\u83b7\u5f97FDA\u6279\u51c6<\/span><\/strong><\/p>\n

6\u67088\u65e5\uff0c\u7f8e\u56fd\uff0cGenentech\u516c\u53f8\u4eca\u65e5\u5ba3\u5e03FDA\u5df2\u6279\u51c6Venetoclax\u4e0e\u5229\u59a5\u6614\u5355\u6297\uff08Rituximab\uff09\u8054\u5408\u4f7f\u7528\uff0c\u7528\u4e8e\u6cbb\u7597\u60a3\u6709\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08CLL\uff09\u6216\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08SLL\uff09\u7684\u60a3\u8005\u3002Venclexta\u662f\u4e00\u6b3e\u9009\u62e9\u6027\u7684BCL-2\u6291\u5236\u5242\uff0c\u6291\u5236\u5728\u6162\u6027\u6dcb\u5df4\u6027\u767d\u8840\u75c5\u4e2d\u8fc7\u91cf\u8868\u8fbe\u7684BCL-2\u86cb\u767d\u3002\u8be5\u86cb\u767d\u5728\u7ec6\u80de\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u7684\u8fc7\u7a0b\u4e2d\u8d77\u5230\u4e86\u91cd\u8981\u4f5c\u7528\uff0c\u800c\u6291\u5236\u5b83\u7684\u529f\u80fd\u6709\u671b\u91cd\u5851\u7ec6\u80de\u7684\u5173\u952e\u4fe1\u53f7\u901a\u8def\u3002Rituxan\u662f\u4e00\u6b3e\u9776\u5411CD20\u7684\u5355\u514b\u9686\u6297\u4f53\uff0c\u80fd\u6709\u6548\u5bf9\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u8fdb\u884c\u6cbb\u7597\u3002\u524d\u671f\u7684\u7814\u7a76\u6570\u636e\u663e\u793a\uff0c\u63a5\u53d7Venclexta\u4e0eRituxan\u7684\u6cbb\u7597\u80fd\u663e\u8457\u51cf\u5c11\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u7684\u98ce\u9669\u8fbe81%\u3002<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n


<\/span><\/strong><\/p>\n

2018 ASCO\u90e8\u5206\u6297\u4f53\u836f\u7814\u7a76\u4fe1\u606f\u901f\u9012<\/span><\/strong><\/p>\n

 <\/span><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

8<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Innate Pharma SA\u5c55\u793a\u4e86\u5176\u5728\u7ed3\u76f4\u80a0\u764c\u6cbb\u7597\u65b9\u9762\u76841\u671f\u4e34\u5e8a\u7814\u7a76\u8fdb\u5c55<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u6cd5\u56fd\uff0cInnate Pharma SA\u4eca\u65e5\u5728<\/span>ASCO\u5927\u4f1a\u4e0a\u5c55\u793a\u4e86<\/span>\u8fdb\u884c\u7684\u6cbb\u7597<\/span>\u590d\u53d1\u6027\/\u8f6c\u79fb\u6027\u5fae\u536b\u661f\u7a33\u5b9a\u7ed3\u76f4\u80a0\u764c<\/span>1\u671f\u4e34\u5e8a\u7684\u6700\u65b0\u7814\u7a76\u6570\u636e\u3002\u8be5\u7814\u7a76\u8bc4\u4f30\u4e86\u9776\u5411NK\u548cT\u7ec6\u80de\u68c0\u67e5\u70b9\u53d7\u4f53NKG2A\u7684\u5355\u514b\u9686\u6297\u4f53Monalizuma\u8054\u5408Durvalumab\u6cbb\u7597\u590d\u53d1\u6216\u8f6c\u79fb\u6027\u5fae\u536b\u661f\u7a33\u5b9a\u7ed3\u76f4\u80a0\u764c\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u521d\u6b65\u7684\u6570\u636e\u663e\u793a\u8054\u5408\u7528\u836f\u5bf9\u8fd9\u79cd\u96be\u4ee5\u6cbb\u7597\u7684\u764c\u75c7\u7c7b\u578b\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u6cbb\u7597\u7b2c16\u5468\u7ea631%\u7684\u60a3\u8005\u75be\u75c5\u8fdb\u5c55\u5f97\u5230\u6709\u6548\u63a7\u5236\u3002<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n


<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

9<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

FibroGen<\/span>\u5c55\u793a\u4e86Pamrevlumab\u6cbb\u7597\u80f0\u817a\u764c\u7684\u4e34\u5e8a\u7814\u7a76\u8fdb\u5c55<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0cFibroGen\u4eca\u65e5\u5728ASCO\u5927\u4f1a\u4e0a\u5c55\u793a\u4e86Pamrevlumab\u8054\u5408\u6807\u51c6\u5316\u7597\u6cbb\u7597\u5c40\u90e8\u665a\u671f\u4e0d\u80fd\u5207\u9664\u80f0\u817a\u764c\uff08LAPC\uff09\u7684I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u3002\u5728\u8fd9\u9879\u5f00\u653e\u6807\u7b7e\u968f\u673aI\/II<\/span>\u671f\u4e34\u5e8a\u7814\u7a76\u4e2d\uff0cPamrevlumab\u4e0e\u6807\u51c6\u5316\u7597\uff08<\/span>\u5409\u897f\u4ed6\u6ee8\u3001\u7d2b\u6749\u9187<\/span>\uff09\u8054\u5408\u7ed9\u836f\uff0c\u4e0e\u5355\u72ec\u5316\u7597\u8fdb\u884c\u4e34\u5e8a\u83b7\u76ca\u6bd4\u8f83\u3002\u7ed3\u679c\u663e\u793a\u8054\u5408\u7ed9\u836f\u6cbb\u7597\u7ec4\u7684\u80bf\u7624\u83b7\u5f97\u4e0d\u540c\u7a0b\u5ea6\u7684\u964d\u671f\uff0c\u62e5\u6709\u66f4\u9ad8\u6bd4\u4f8b\u7684\u60a3\u8005\u518d\u6b21\u63a5\u53d7\u624b\u672f\u5207\u9664\u6cbb\u7597\uff08<\/span>70.8 % VS 15.4 %<\/span>\uff09\u3002\u5728\u5176\u540e\u7684\u751f\u5b58\u968f\u8bbf\u6570\u636e\u663e\u793a\uff0c\u6210\u529f\u8fdb\u884c\u624b\u672f\u5207\u9664\u7684\u60a3\u8005\u4e0e\u672a\u8fdb\u884c\u5207\u9664\u7684\u60a3\u8005\u76f8\u6bd4\uff0c\u4e2d\u4f4d\u751f\u5b58\u671f\u66f4\u957f\uff08<\/span>40\u6708VS 18.6\u6708<\/span>\uff09\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u5c40\u90e8\u665a\u671f\u80f0\u817a\u764c\uff08\u65e0\u8f6c\u79fb\uff09\u60a3\u8005\u9884\u540e\u4e0d\u826f\uff0c\u4e2d\u4f4d\u751f\u5b58\u671f\u4e3a9-18\u4e2a\u6708\u3002\u6b64\u7c7b\u60a3\u8005\u5982\u679c\u83b7\u5f97R0\u7ea7\u522b\u624b\u672f\u5207\u9664\u5219\u53ef\u83b7\u5f97\u66f4\u957f\u7684\u751f\u5b58\u5468\u671f\u3002Pamrevlumab\u662f\u4e00\u79cd\u9776\u5411\u7ed3\u7f14\u7ec4\u7ec7\u751f\u957f\u56e0\u5b50\uff08CTGF\uff09\u7684\u5355\u514b\u9686\u6297\u4f53\uff0c\u8ba1\u5212\u5f00\u53d1\u7528\u4e8e\u6cbb\u7597\u7ea4\u7ef4\u5316\u548c\u7ea4\u7ef4\u589e\u751f\u6027\u75be\u75c5\u3002\u76ee\u524d\u7684\u6570\u636e\u8bc1\u5b9ePamrevlumab\u8054\u5408\u5316\u7597\u6709\u53ef\u80fd\u4e3a\u5c40\u90e8\u665a\u671f\u4e0d\u53ef\u5207\u9664\u80f0\u817a\u764c\u60a3\u8005\u63d0\u4f9b\u65b0\u8f85\u52a9\u6cbb\u7597\u65b9\u6848\u3002<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/span><\/p>\n


<\/span><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

10<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Immunomedics<\/span>\u516c\u5e03\u4e86\u5176ADC\u836f\u7269\u6cbb\u7597ER\u9633\u6027\u4e73\u817a\u764c\u7684\u7814\u7a76\u6570\u636e<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0cImmunomedics\u5728ASCO\u5e74\u4f1a\u4e0a\u53e3\u5934\u4ecb\u7ecd\u4e86\u5176ADC\u836f\u7269\u6cbb\u7597ER\u9633\u6027\u4e73\u817a\u764c\u7684\u7814\u7a76\u6570\u636e\u3002\u8fd9\u9879I\/II<\/span>\u671f\u7814\u7a76\u8bc4\u4f30\u4e86Sacituzumab govitecan\u5bf9\u4e8e\u5904\u4e8e\u665a\u671f\u96cc\u6fc0\u7d20\u53d7\u4f53\u9633\u6027\/\u4eba\u7c7b\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f532\u9634\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6839\u636e\u7814\u7a76\u8005\u8bc4\u4f30\uff0c54\u540d\u63a5\u53d7\u6cbb\u7597\u7684\u60a3\u8005\u83b7\u5f9731%\u7684\u4e34\u5e8a\u5e94\u7b54\u7387\uff0c\u4e2d\u4f4d\u53cd\u5e94\u6301\u7eed\u65f6\u95f4\u4e3a7.4\u4e2a\u6708\uff0c\u4e34\u5e8a\u83b7\u76ca\u7387\u4e3a48% \u3002\u60a3\u8005\u5bf9Sacituzumab govitecan\u7684\u6cbb\u7597\u8010\u53d7\u6027\u826f\u597d\uff0c\u6ca1\u6709\u4e0e\u6cbb\u7597\u76f8\u5173\u7684\u6b7b\u4ea1\u4e8b\u4ef6\u53d1\u751f\u3002\u60a3\u6709ER\u9633\u6027\/HER2\u9634\u6027\u7684\u4e73\u817a\u764c\u5973\u6027\u5728\u521d\u671f\u7684\u5185\u5206\u6ccc\u6cbb\u7597\u548c\u5316\u7597\u65b9\u9762\u80fd\u591f\u83b7\u5f97\u4e00\u5b9a\u4e34\u5e8a\u83b7\u76ca\uff0c\u4f46\u662f\u540e\u671f\u7684\u6cbb\u7597\u9009\u62e9\u975e\u5e38\u6709\u9650\u3002\u57fa\u4e8e\u4eca\u5929\u7684\u7ed3\u679c\uff0cSacituzumab govitecan\u53ef\u80fd\u4e3a\u6b64\u7c7b\u60a3\u8005\u63d0\u4f9b\u4e00\u79cd\u65b0\u7684\u63a7\u5236\u75be\u75c5\u8fdb\u5c55\u7684\u6709\u6548\u9009\u62e9\u3002<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n


<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

11<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Nivolmab\u5e94\u7528\u4e8e\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u6cbb\u7597\u83b7\u76ca\u663e\u8457<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0cBMS\u4eca\u65e5\u5728ASCO\u5e74\u4f1a\u4e0a\u516c\u5e03Opdivo\u4e00\u7ebf\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7684\u90e8\u5206\u6570\u636e\u3002\u8fd9\u9879III\u671f\u4e34\u5e8aCheckMate-227\u7814\u7a76\u8bc4\u4f30\u4e86<\/span>Nivolmab<\/span>\u8054\u5408\u5c0f\u5242\u91cfYervoy\u76f8\u6bd4\u4e8eNivolmab\u8054\u5408\u5316\u7597\u5bf9\u4e8ePD-L1\u8868\u8fbe<1%\u7684\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\u6cbb\u7597\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6570\u636e\u663e\u793a\uff0c\u5728PD-L1\u8868\u8fbe<1%\u7684\u60a3\u8005\u4e2d\uff0cOpdivo\u52a0\u5316\u7597\uff08n=177\uff09\u5ef6\u957f\u4e86\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u3002\u5728\u5bf9\u9ad8\u80bf\u7624\u7a81\u53d8\u8d1f\u8377\uff08TMB\uff09\u226510\u4e2a\u7a81\u53d8\u7076\u548cPD-L1\u8868\u8fbe<1%\u60a3\u8005\u7684\u63a2\u7d22\u6027\u5206\u6790\u4e2d\uff0cOpdivo\u52a0\u5c0f\u5242\u91cfYervoy\uff08n=38\uff09\u3001Opdivo\u52a0\u5316\u7597\uff08n=43\uff09\u548c\u5316\u7597\uff08n=48\uff09\u7684\u4e00\u5e74PFS\u7387\u5206\u522b\u4e3a45%\u300127%\u548c8%\u3002\u5728\u4f4eTMB\u548cPD-L1<1%\u7684\u60a3\u8005\u4e2d\uff0cOpdivo\u52a0\u5c0f\u5242\u91cfYervoy\uff08n=52\uff09\u548cOpdivo\u52a0\u5316\u7597\uff08n=54\uff09\u7684\u4e00\u5e74PFS\u7387\u4e3a18%\uff0c\u5316\u7597\uff08n=59\uff09\u7684\u4e00\u5e74PFS\u7387\u4e3a16%\u3002\u7ed3\u679c\u663e\u793a\uff0cOpdivo\u8054\u5408\u5316\u7597\u6539\u5584\u4e86\u4e00\u7ebf\u80ba\u764c\u60a3\u8005\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u7387\uff0cOpdivo\u52a0\u4f4e\u5242\u91cfYervoy\u4e3a\u9ad8TMB\u60a3\u8005\u63d0\u4f9b\u4e86\u6301\u4e45\u7684\u7597\u6548\u3002<\/span> <\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n


<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

12<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Merck\u665a\u671f\u5c0f\u7ec6\u80de\u80ba\u764cKEYNOTE-158\u7814\u7a76\u83b7\u5f97\u79ef\u6781\u8fdb\u5c55<\/span><\/strong><\/p>\n

\u540c\u65f6\u5176KEYTRUDA\u00ae\uff08<\/span><\/strong>P<\/span><\/strong>embrolizumab<\/span><\/strong>\uff09<\/span><\/strong>\u6cbb\u7597\u9ed1\u8272\u7d20\u7624\u83b7\u76ca\u663e\u8457<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0cMerk\u516c\u53f8\u4eca\u65e5\u5ba3\u5e03\u4e86II\u671f\u4e34\u5e8aKEYNOTE-158\u7814\u7a76\u7684\u4e2d\u671f\u6570\u636e\u3002\u8be5\u7814\u7a76\u8bc4\u4ef7KEYTRUDA\u4f5c\u4e3a\u5355\u4e00\u7597\u6cd5\u5bf9\u4ee5\u524d\u63a5\u53d7\u8fc7\u6cbb\u7597\u7684\u665a\u671f\u5c0f\u7ec6\u80de\u80ba\u764c\uff08SCLC\uff09\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u7814\u7a76\u7ed3\u679c\u663e\u793a\uff0cSCLC\u961f\u5217\u4e2d\u60a3\u8005\u7684\u603b\u4f53\u5e94\u7b54\u7387\uff08ORR\uff09\u4e3a18.7 % \uff0c\u6b64\u5916\u5728\u9884\u5148\u6307\u5b9a\u7684\u63a2\u7d22\u6027\u5206\u6790\u4e2d\uff0c\u9ad8\u8868\u8fbePD-L1\u4e14\u8054\u5408\u8bc4\u5206\uff08CPS\uff09\u22651\u7684\u60a3\u8005\u7684ORR\u4e3a35.7%\u3002KEYTRUDA\u5728\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\u4eba\u7fa4\u4e2d\uff0c\u5c55\u793a\u51fa\u8f83\u9ad8\u7684\u6574\u4f53\u53cd\u5e94\u7387\uff0c\u540e\u7eed\u7814\u7a76\u8005\u5c06\u5728III\u671f\u4e34\u5e8a KEYNOTE-604\u7814\u7a76\u4e2d\u7ee7\u7eed\u8bc4\u4f30KEYTRUDA\u8054\u5408\u5316\u7597\u4f5c\u4e3a\u5e7f\u6cdb\u671f\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\u4e00\u7ebf\u6cbb\u7597\u7684\u6f5c\u529b\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u540c\u4e00\u65f6\u95f4Merk\u516c\u5e03\u4e86III\u671fKEYNOTE-006\u7814\u7a76\u548cIb\u671fKEYNOTE-001\u7814\u7a76\u5728\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u4e2d\u7684\u957f\u671f\u7597\u6548\u6570\u636e\u3002KEYNOTE-006\u7684\u4e00\u9879\u65b0\u5206\u6790\u663e\u793a\uff0c\u5728\u5b8c\u6210\u4e24\u5e74KEYTRUDA\u6cbb\u7597\u7684\u60a3\u8005\u4e2d\uff0c\u603b\u4f53\u751f\u5b58\u7387\u6570\u636e\u6697\u793a\u60a3\u8005\u80fd\u591f\u83b7\u5f97\u6301\u4e45\u7684\u7597\u6548\uff0c\u4e2d\u4f4d\u751f\u5b58\u671f\u4e3a20.3\u4e2a\u6708\uff0c86%\u7684\u60a3\u8005\u4fdd\u6301\u80bf\u7624\u65e0\u8fdb\u5c55\u3002KEYTRUDA\u5728\u4e24\u9879\u7814\u7a76\u4e2d\u7684\u5b89\u5168\u72b6\u51b5\u4e0e\u5148\u524d\u5728\u665a\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u4e2d\u7684\u8bd5\u9a8c\u4e2d\u6240\u89c1\u4e00\u81f4\u3002\u7ed3\u5408\u6700\u65b0\u7684\u7814\u7a76\u6570\u636e\uff0c\u4e0d\u8bba\u80bf\u7624BRAF\u7a81\u53d8\u72b6\u6001\u5982\u4f55\uff0cKEYTRUDA\u90fd\u80fd\u591f\u663e\u8457\u5ef6\u957f\u4e00\u7ebf\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684\u5b58\u6d3b\u65f6\u95f4\u3002<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n


<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

13<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Immunocore\u516c\u53f8\u81f4\u529b\u4e8e\u7f55\u89c1\u773c\u90e8\u764c\u75c7\u7684\u4e34\u5e8a\u7814\u7a76\u83b7\u5f97\u79ef\u6781\u8fdb\u5c55<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0c<\/span>Immunocore\u516c\u53f8<\/span>\u4eca\u65e5\u5728ASCO\u5e74\u4f1a\u4e0a\u5c55\u793a\u4e86IMCgp100\u6cbb\u7597\u9ed1\u8272\u7d20\u7624\u7684\u6700\u65b0\u7814\u7a76\u8fdb\u5c55\u3002\u63a5\u53d7Imcgp100\u6cbb\u7597\u7684\u8461\u8404\u819c\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u80fd\u591f\u83b7\u5f97\u6301\u4e45\u7684\u4e34\u5e8a\u5e94\u7b54\uff0c\u60a3\u8005\u7684\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u4e3a19.1\u4e2a\u6708\uff0c\u76ee\u524d\u5c1a\u672a\u8fbe\u5230\u4e2d\u4f4d\u603b\u4f53\u751f\u5b58\u7387\u3002\u5728\u6570\u636e\u7edf\u8ba1\u622a\u6b62\u65f6\u95f4\uff0cImcgp100\u6cbb\u7597\u768419\u540d\u60a3\u8005\u7684\u5ba2\u89c2\u5e94\u7b54\u738718% \uff0c\u4e00\u5e74\u603b\u751f\u5b58\u738774%\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u8461\u8404\u819c\u9ed1\u8272\u7d20\u7624\u867d\u7136\u7f55\u89c1\uff0c\u4f46\u5374\u662f\u6210\u4eba\u773c\u90e8\u764c\u75c7\u7684\u6700\u5e38\u89c1\u5f62\u5f0f\u3002\u5f53\u8461\u8404\u819c\u9ed1\u8272\u7d20\u7624\u8f6c\u79fb\u5230\u773c\u775b\u4ee5\u5916\u65f6\uff0c\u53ea\u6709\u4e0d\u5230\u4e00\u534a\u7684\u60a3\u8005\u80fd\u5b58\u6d3b\u4e00\u5e74\u3002\u8461\u8404\u819c\u9ed1\u8272\u7d20\u7624\u7684\u5b58\u6d3b\u7387\u51e0\u5341\u5e74\u6765\u57fa\u672c\u4e0a\u6ca1\u6709\u53d8\u5316\uff0c\u4e00\u65e6\u53d1\u5c55\u6210\u8f6c\u79fb\u6027\u75be\u75c5\uff0c\u5c31\u5f88\u96be\u6cbb\u7597\u3002Immunocore\u516c\u53f8\u7684\u7814\u7a76\u6570\u636e\u6709\u529b\u8bc1\u660eImcgp100\u53ef\u80fd\u4e3a\u8fd9\u4e00\u5f97\u4e0d\u5230\u5145\u5206\u6cbb\u7597\u7684\u60a3\u8005\u7fa4\u4f53\u5e26\u6765\u5e0c\u671b\u3002<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n

 <\/p>\n

\n
\n
\n
\n
\n

14<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

MersanaTherapeutics<\/span>\u516c\u53f8ADC\u65b0\u836f\u83b7\u5f97\u521d\u6b65\u8fdb\u5c55<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0cMersana Therapeutics\u516c\u53f8\u516c\u5e03\u4e86\u5176\u6700\u65b0ADC\u836f\u7269\u7684\u4e34\u5e8a\u7814\u7a76\u8fdb\u5c55\u3002XMT-1522\u662f\u5176\u6700\u65b0\u7814\u7a76\u7684\u9776\u5411HER2\u86cb\u767d\u7684ADC\u836f\u7269\uff0c\u76ee\u524d\u5904\u4e8eI\u671f\u4e34\u5e8a\u7684\u5242\u91cf\u9012\u589e\u548c\u6269\u5c55\u7814\u7a76\u4e2d\uff0c\u6b63\u5728\u8bc4\u4f30\u5176\u5bf9\u4e8e\u8868\u8fbeHER2\u7684\u4e73\u817a\u764c\u3001\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u548c\u80c3\u764c\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u622a\u6b622018\u5e744\u670821\u65e5\uff0c22\u540d\u60a3\u8005( 18\u540d\u4e73\u817a\u764c\u30013\u540d\u80c3\u764c\u30011\u540d\u80c6\u56ca\u764c)\u5df2\u7ecf\u5b8c\u6210\u4e866\u4e2a\u5242\u91cf\u6c34\u5e73\u7684\u5242\u91cf\u9650\u5236\u6bd2\u6027\uff08DLT\uff09\u8bc4\u4f30\u7814\u7a76\uff0c\u5176\u4e2d\u670911\u4eba\u60a3\u8005\u7684\u80bf\u7624\u8fdb\u5c55\u5f97\u5230\u4e0d\u540c\u7a0b\u5ea6\u7684\u63a7\u5236\u3002\u603b\u4f53\u800c\u8a00\uff0c\u60a3\u8005\u5bf9\u4e8e\u6cbb\u7597\u7684\u8010\u53d7\u6027\u826f\u597d\uff0c\u5927\u591a\u6570\u4e0d\u826f\u4e8b\u4ef6\uff08AEs\uff09\u7ea7\u522b\u8f83\u4f4e\u4e14\u53ef\u63a7\u3002<\/span><\/p>\n

<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n


<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

15<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Idera Pharmaceuticals\u4e3a<\/span>PD-1\u7597\u6cd5\u5e94\u7b54\u4e0d\u4f73\u9ed1\u8272\u7d20\u7624<\/span>\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7b56\u7565<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0cIdera Pharmaceuticals\u516c\u53f8\u5728\u4eca\u65e5\u7684ASCO\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e86\u6b63\u5728\u8fdb\u884c\u7684light-204\u8bd5\u9a8c\u7684\u7ed3\u679c\u3002\u8be5\u8bd5\u9a8c\u7814\u7a76\u4e86Indera\u7684TLR9\u6fc0\u52a8\u5242T<\/span>ilsotolimod<\/span>\u8054\u5408Ipilimumab\u6cbb\u7597\u5bf9PD-1\u7597\u6cd5\u5e94\u7b54\u4e0d\u4f73\u9ed1\u8272\u7d20\u7624\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u76ee\u524d\u7684\u6570\u636e\u663e\u793a\u8054\u5408\u7597\u6cd5\u80fd\u591f\u5b9e\u73b038%\u7684\u603b\u6709\u6548\u7387\uff08ORR\uff09\u3002 <\/span><\/p>\n


<\/span><\/p>\n

\u73b0\u9636\u6bb5\u4e34\u5e8a\u4e2d\u63a5\u53d7Pembrolizumab\u6cbb\u7597\u7684\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u60a3\u8005\uff0c\u5728\u75be\u75c5\u8fdb\u5c55\u65f6\u6539\u7528\u5355\u5242Ipilimumab\u6cbb\u7597\u7684ORR\u4e3a13%\u3002\u800clight-204\u7814\u7a76\u4e2d\u89c2\u5bdf\u5230\u768438%\u7684ORR\u662f\u7279\u522b\u4ee4\u4eba\u9f13\u821e\u8fdb\u5c55\uff0c\u8868\u660e\u6b64\u8054\u5408\u7597\u6cd5\u662f\u6cbb\u7597\u8f6c\u79fb\u6027\u9ed1\u7d20\u7624\u7684\u53ef\u884c\u65b9\u6848\u3002\u9274\u4e8e\u6b64\u79ef\u6781\u7684\u8fdb\u5c55\uff0cIdera\u4e8e2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\u542f\u52a8\u4e86Tilsotolimod\u8054\u5408Ipilimumab\u6cbb\u7597PD-1\u7597\u6cd5\u96be\u6cbb\u6027\u9ed1\u8272\u7d20\u7624\u7684\u5168\u7403III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n


<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

16<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Merck KgaA\u80bf\u7624\u514d\u75ab\u65b0\u7597\u6cd5\u7684\u63a2\u7d22\u53d6\u5f97\u521d\u6b65\u8fdb\u5c55<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0cMerck KgaA\u4eca\u65e5\u5c55\u793a\u5176\u80bf\u7624\u514d\u75ab\u521b\u65b0\u7597\u6cd5<\/span>M824<\/span>\u76841\u671f\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\u3002\u8be5\u9879\u7814\u7a76\u4e0e\u7f8e\u56fd\u56fd\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u5408\u4f5c\u5171\u540c\u8bc4\u4f30\u8be5\u836f\u5bf9\u4e8e\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u548c\u4eba\u7c7b\u4e73\u5934\u72b6\u7624\u75c5\u6bd2\uff08HPV\uff09\u76f8\u5173\u764c\u75c7\u7684\u6cbb\u7597\u6548\u679c\uff0c\u8fdb\u4e00\u6b65\u8bc1\u660e\u5c06TGF-\u03b2\u9677\u9631\u4e0e\u6297PD-L1\u7597\u6cd5\u7ed3\u5408\u5728\u4e00\u8d77\u5c06\u4ea7\u751f\u66f4\u6709\u6548\u7684\u4e34\u5e8a\u76f8\u5173\u6297\u80bf\u7624\u6d3b\u6027\u3002\u8bd5\u9a8c\u6570\u636e\u663e\u793a\uff0c\u7ecf\u53d7M824\u6cbb\u7597\u7684PD-L1\u9633\u6027\u80bf\u7624\u60a3\u8005\u83b7\u5f9740.7%\uff0811\/27\uff09\u7684\u603b\u6709\u6548\u7387\uff08ORR\uff09\uff0c\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u4e3a6.8\u4e2a\u6708\uff0c\u5176\u4e2dPD-L1\u9633\u6027\u7684\u9ad8\u80bf\u7624\u8d1f\u8377\u60a3\u8005\u7684ORR\u4e3a71.4%\uff085\/7\uff09\u3002\u6b64\u5916\uff0cHPV\u76f8\u5173\u764c\u75c7\u60a3\u8005\u7684ORR\u4e3a35.3%\u3002<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n


<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

17<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Agenus<\/span>\u4ecb\u7ecd\u4e86\u65b0\u7684\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7684\u4e34\u5e8a\u7814\u7a76\u6570\u636e<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u7f8e\u56fd\uff0cAgenus\u4eca\u65e5\u5728\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u5e74\u4f1a\u4e0a\u4ecb\u7ecd\u4e86\u5176\u5728\u7814\u7684\u6297CTLA-4\uff08<\/span>AGEN1884<\/span>\uff09\u548c\u6297PD-1\uff08<\/span>AGEN2034<\/span>\uff09\u836f\u7269\u7684\u6700\u65b0\u4e34\u5e8a\u6570\u636e\u3002100\u591a\u540d\u665a\u671f\u96be\u6cbb\u6027\u764c\u75c7\u60a3\u8005\u63a5\u53d7\u4e86AGEN1884\u6216AGEN2034\u7684\u6cbb\u7597\uff0c\u5728\u53ef\u8bc4\u4f30\u7684\u60a3\u8005\u4e2d\u5206\u522b\u89c2\u5bdf\u523031%\u548c42%\u7684\u4e34\u5e8a\u83b7\u76ca\u7387\u3002\u4e24\u79cd\u6297\u4f53\u5728\u957f\u65f6\u95f4\u66b4\u9732\u4e0b\u90fd\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u63a8\u8350\u5242\u91cf\u88ab\u9009\u62e9\u7528\u4e8e\u540e\u7eed\u7684\u5bab\u9888\u764cII\u671f\u4e34\u5e8a\u7814\u7a76\u4e2d\u3002<\/span><\/p>\n

<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n


<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n

18<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

Alexo Therapeutics<\/span>\u63a2\u7d22\u665a\u671f\u5b9e\u4f53\u7624\u548c\u6dcb\u5df4\u7624\u7684\u65b0\u7597\u6cd5<\/span><\/strong><\/p>\n

6\u67084\u65e5\uff0c\u4ee5\u8272\u5217\uff0cAlexo Therapeutics\u516c\u53f8\u4eca\u65e5\u4ecb\u7ecd\u4e86\u5176\u4e3b\u8981\u5019\u9009\u4ebaALX148\u7684\u9996\u6b21\u4eba\u4f531\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u6570\u636e\u3002\u8bd5\u9a8c\u7684\u521d\u6b65\u7ed3\u679c\u663e\u793a\uff0c\u5728\u665a\u671f\u5b9e\u4f53\u7624\u548c\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u60a3\u8005\u4e2d\uff0cALX148\u65e0\u8bba\u662f\u8054\u5408T\u7ec6\u80de\u68c0\u67e5\u70b9\u6291\u5236\u3001\u9776\u5411\u6297\u764c\u6297\u4f53\u8fd8\u662f\u4f5c\u4e3a\u5355\u4e00\u836f\u7269\u6cbb\u7597\u5747\u8868\u73b0\u51fa\u826f\u597d\u7684\u8010\u53d7\u6027\u3002\u6700\u5e38\u89c1\u7684\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u662f\u75b2\u52b3\uff0814%\uff09\u548c\u5934\u75db\uff0811%\uff09\uff0c\u5927\u591a\u6570\u4e0e\u6cbb\u7597\u76f8\u5173\u7684\u4e0d\u826f\u4e8b\u4ef6\u4e3a1\u7ea7\u62162\u7ea7\u3002<\/span><\/p>\n


<\/span><\/p>\n

ALX148\u662f\u4e00\u79cd\u878d\u5408\u86cb\u767d\uff0c\u7531\u4eba\u514d\u75ab\u7403\u86cb\u767d\u7684\u975e\u6d3b\u6027Fc\u533a\u8fde\u63a5\u5de5\u7a0b\u5316\u9ad8\u4eb2\u548c\u529b\u7684CD47\u7ed3\u6784\u57df\u7ec4\u6210\u3002ALX148\u6709\u6548\u7279\u5f02\u6027\u7ed3\u5408CD47\uff0c\u963b\u65ad\u5176\u4e0eSIRP\u03b1\u7684\u76f8\u4e92\u4f5c\u7528\uff0c\u4ece\u800c\u6291\u5236\u764c\u7ec6\u80de\u589e\u6b96\u76f8\u5173\u7684\u5173\u952e\u514d\u75ab\u68c0\u67e5\u70b9\u4fe1\u53f7\u901a\u8def\u3002\u5728\u4e34\u5e8a\u524d\u7814\u7a76\u4e2d\uff0cALX148\u7ed3\u5408\u9776\u5411\u6297\u764c\u6297\u4f53\u548c\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff0c\u80fd\u591f\u589e\u5f3a\u6297\u80bf\u7624\u53cd\u5e94\u3002<\/span><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"<\/p>\n

<\/span>
<\/p>\n

\n
\n

\u6b22\u8fce\u52a0\u5165\u5c0f\u7f16\u56e2\u961f\u6210\u4e3a\u5c0f\u7f16\u4e00\u5458<\/strong><\/span><\/strong><\/span><\/p>\n

\u8bf7\u52a0\u5c0f\u7f16\u5fae\u4fe1\u53f7\uff1awuwenjun7237<\/span><\/strong><\/span><\/span><\/p>\n

\u5982\u6709\u6280\u672f\u89e3\u8bfb\u3001\u884c\u4e1a\u6d1e\u89c1\u613f\u610f\u5206\u4eab<\/span><\/strong><\/span><\/p>\n

\u6b22\u8fce\u6295\u7a3f\u5230\u5c0f\u7f16\u90ae\u7bb1\uff1awuwj06@163.com<\/strong><\/span><\/strong><\/span><\/strong><\/span><\/span><\/span><\/strong><\/p>\n

\"\u6bcf\u5468\u6297\u4f53\u836f\u8baf20180604-20180610\"
<\/p>\n

\n
\n
\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
<\/section>\n
<\/section>\n<\/section>\n
\n
\n
<\/span><\/strong><\/span>\u7248<\/section>\n<\/section>\n
\n
\u6743<\/section>\n<\/section>\n
\n
\u58f0<\/section>\n<\/section>\n
\n
\u660e<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u6b22\u8fce\u4e2a\u4eba\u8f6c\u53d1\u5206\u4eab\u3002\u5176\u4ed6\u4efb\u4f55\u5a92\u4f53\u3001\u7f51\u7ad9\u5982\u9700\u8f6c\u8f7d\u6216\u5f15\u7528\u672c\u7f51\u7248\u6743\u6240\u6709\u5185\u5bb9\u987b\u83b7\u5f97\u6388\u6743\u4e14\u5728\u9192\u76ee\u4f4d\u7f6e\u5904\u6ce8\u660e\u201c\u8f6c\u81ea\uff1a\u751f\u7269\u5236\u836f\u5c0f\u7f16\u201d\u3002<\/span><\/p>\n

\n
\n
<\/section>\n
<\/section>\n
<\/section>\n<\/section>\n
\n
\n


\u575a\u6301\u539f\u521b\u3001\u575a\u6301\u4e13\u4e1a<\/strong><\/span><\/p>\n

\u6b22\u8fce\u5173\u6ce8<\/strong><\/span>\u751f\u7269\u5236\u836f\u5c0f\u7f16<\/strong><\/span><\/span><\/p>\n

\u6295\u7a3f\u4fe1\u7bb1\uff1awuwj06@163.com<\/span><\/p>\n

\u5c0f\u7f16\u56e2\u961f\u73b0\u670921\u4f4d\u6210\u5458\uff1a<\/strong><\/span><\/span><\/p>\n

Armstrong\u3001\u533b\u836f\u5c40\u5916\u4eba\u3001Fairy\u3001<\/span>Jone\u3001<\/span>\u4e1c\u80dc\u897f\u725b\u3001Alpharesearcher\u3001MT\u3001\u767e\u8349\u3001Irene\u3001<\/span>Self Renew\u3001\u86cb\u767d\u5de5\u4eba\u3001At.Zhou\u3001Julia\u3001\u6e38\u65b9\u548c\u5c1a\u3001Grand\u3001\u5915\u9633\u6b66\u58eb\u3001\u5403\u74dc\u7fa4\u4f17\u3001Nathan\u3001\u795e\u7ecf\u5143\u3001Clear\u516e\u3001\u5357\u5c71\u5357<\/span><\/span><\/p>\n

\u6b22\u8fce\u6709\u5171\u540c\u5174\u8da3\u7684\u670b\u53cb\u52a0\u5165<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n

\n
<\/section>\n
<\/section>\n<\/section>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n
\n

\u59cb\u53d1\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7\uff1a \u751f\u7269\u5236\u836f\u5c0f\u7f16 <\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u4f5c\u8005 l \u653e\u7fc1\u662f\u6c34\u8d27 \u7f16\u8f91 l \u7ec6\u80de\u623f\u95f4 1 Clovis Oncology\u548cI […]<\/p>\n","protected":false},"author":1,"featured_media":8449,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/8448"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=8448"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/8448\/revisions"}],"predecessor-version":[{"id":8463,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/8448\/revisions\/8463"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/8449"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=8448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=8448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=8448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}